Streetbeat News

Acquisitions Mergers

ABBV

AbbVie has acquired Celsius Therapeutics for $250 million in cash. Celsius' CEL383, a potential first-in-class anti-TREM1 antibody, is aimed at treating inflammatory bowel disease (IBD).

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 1:28 pm

SYTA

Siyata Mobile Inc. (NASDAQ:SYTA) has announced the pricing of a public offering worth approximately $6 million, consisting of common shares and pre-funded warrants. The offering is priced at $0.58 per share, with proceeds intended for working capital, corporate purposes, marketing, strategic investments, and potential future acquisitions.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 1:07 pm

VNDA

Vanda Pharmaceuticals Inc. shares are trading lower after Future Pak withdrew its proposal to purchase the company.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 1:03 pm

CLSK

GRDI

CleanSpark has entered into a definitive merger agreement to acquire GRIID Infrastructure for $155 million. The acquisition is expected to add over 400 MW in Tennessee over the next two years, bringing CleanSpark's total capacity to over 1 GW.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 1:02 pm

VNDA

Future Pak has announced the withdrawal of its proposal to purchase Vanda Pharmaceuticals Inc. This decision could impact Vanda's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 1:02 pm

TH

Target Hospitality shares are trading higher after the company announced that its Special Committee is reviewing TDR's $10.80 per share proposal. Despite cutting its FY24 revenue guidance, the company expects to achieve zero net debt by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:50 pm

CASI

CASI Pharmaceuticals shares are trading higher following the announcement of plans to submit an Investigational New Drug application to the FDA for CID-103, aimed at treating antibody-mediated rejection in kidney transplant recipients. Additionally, the company received a preliminary non-binding proposal from CEO and Chairman Wei-Wu He to acquire its business operations in China.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:49 pm

CASI

MEDS

RXRX

Market-Moving News for June 27th includes significant updates from CASI Pharmaceuticals, TRxADE HEALTH, and Recursion Pharmaceuticals. CASI plans to submit a CID-103 IND application and received a non-binding proposal to acquire its China business for $40M. TRxADE HEALTH shares are up following their Q1 financial results. Recursion Pharmaceuticals announced the pricing of its public offering of 30,769,230 shares at $6.50 per share, leading to a drop in share price.

Portfolio Pulse from ryanfaloona@benzinga.com

June 27, 2024 | 12:37 pm

CHRS

Coherus BioSciences has announced the divestment of its Hong Kong King-Friend Industrial Co. Ltd. for a cash consideration of $40 million.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:31 pm

GAN

GAN Limited has received clearance from the Committee on Foreign Investment in the United States (CFIUS) for its proposed merger with a subsidiary of SEGA Sammy Creation, an affiliate of SEGA Sammy Holdings.

Portfolio Pulse from Benzinga Newsdesk

June 27, 2024 | 12:31 pm